IndieBio

indiebio.co

VCMatch tracks IndieBio as an investor focused on Biotech, Medtech, and Pharma companies, Pre-Seed and Growth rounds, and United States, San Francisco, and New York City markets. Upload your deck to compare your startup against the full private matching profile.

Check Size

Not specified

Stages

Pre-Seed, Growth

Focus Areas

Biotech, Medtech, Pharma

Geography

United States, San Francisco, and New York City

Investment Thesis

SOSV/IndieBio is a programmatic, founder‑focused deep‑tech investor that combines pre-seed capital with on‑site lab infrastructure and hands‑on operational support to turn scientific research into companies. They prioritize high‑risk, high‑impact technical ventures (originally in biotech) and have expanded to a broader deep‑tech remit—helping founders with commercialization, go‑to‑market, fundraising and technical validation so science can be brought to market at scale.

Is IndieBio right for your startup?

Upload your pitch deck to compare your startup against VCMatch's private investor profile, including fit, timing, and next-step signals.

See If You're a Match View Sample Match

Investment Focus

Who should take a closer look

IndieBio is most relevant for founders raising Pre-Seed and Growth rounds in Biotech, Medtech, Pharma, and AI/ML, especially across United States, San Francisco, and New York City.

Focus statement

Originally focused on early‑stage biotech with on‑site wet labs and pre‑seed funding, the firm now invests across deep tech — including biotech, materials science, chemistry, applied AI, physics and sustainable industrial solutions — with an emphasis on pre‑seed / programmatic acceleration and follow‑on company building.

Value Add

On‑site lab infrastructure and an accelerator model (historically described as "Silicon Valley’s first biotech program to offer bio‑labs on site as well as pre‑seed investment to scientists ready to launch startups").
Programmatic, hands‑on support: dedicated mentors, operating partners, legal and investor relations teams that work directly on commercialization, go‑to‑market and follow‑on fundraising.
Proven track record and scale: "Between 2015 and 2025, IndieBio’s 310 graduates raised $3.6 billion" demonstrating outcomes from the model.
Multidisciplinary deep‑tech scope: explicit expansion from biotech into chemistry, physics, AI and more ("yes bio but also chemistry, physics, AI, and more.").
Technical leadership and domain expertise in portfolio (CTO/GP roles and partners with scientific backgrounds able to evaluate complex technical claims).
Global, location‑based teams (SOSV NY and SOSV SF) with corporate LP and partnership engagement for strategic collaborations.